December 2016
-
According to Blue Lake Biotechnology, the FDA has agreed to lift a partial clinical hold on a Phase 1/2a clinical trial of BLB201 intranasal RSV vaccine in children aged 8 months to 59 months with… Read more . . .
-
Nasus Pharma announced that it has initiated a Phase 2 study of the company’s NS002 epinephrine nasal powder, which the company is developing for the treatment of anaphylaxis. The open-label PK trial is expected to… Read more . . .
-
According to ReCode Therapeutics, the FDA has cleared the 3rd part of an ongoing Phase 2 trial of nebulized RCT2100 CFTR mRNA therapy in cystic fibrosis patients, and enrollment has opened at US sites. The new… Read more . . .
-
Scottish device developer 1nhaler has announced the closing of a £1.5 million funding led by Archangels, with proceeds intended for continued development the company’s disposable single-use dry powder inhaler. The company says that funds will… Read more . . .
-
Nebulizer maker Aerogen and inhaled interferon developer Synairgen have entered a strategic partnership for development of a custom device for delivery of Synairgen’s SNG001 inhaled interferon-beta, the companies have announced, noting that the new agreement… Read more . . .
-
According to Glenmark Pharmaceuticals, China’s National Medical Products Administration (NMPA) has approved Ryaltris olopatadine hydrochloride / mometasone furoate nasal spray for the treatment of allergic rhinitis. Grand Pharmaceuticals, which acquired the Chinese rights to Ryaltris… Read more . . .
-
MannKind Corporation announced that it has discontinued the Phase 3 ICoN-1 study of MNKD-101 nebulized clofazimine inhalation suspension for the treatment of nontuberculous mycobacterial (NTM) lung disease “due to futility” after analysis of data from the… Read more . . .
-
Chiesi has held an inauguration ceremony for an expanded manufacturing facility in La Chaussée-Saint-Victor, France where the company will manufacture metered dose inhalers with low global warming potential (LGWP) propellants, the company said. Earlier this… Read more . . .
-
Nasal vaccine developer CastleVax has announced the initiation of a Phase 2 study comparing its CVAX-01 intranasal COVID-19 vaccine to an mRNA-based injectable COVID-19 vaccine. The 6-month study is expected to enroll 200 previously-vaccinated adults… Read more . . .
-
Evoke Pharma, which developed and manufactures Gimoti intranasal metoclopramide, has agreed to be acquired by QOL Medical for $11 per share, the companies said. The FDA approved Gimoti for the treatment of diabetic gastroparesis in June 2020. Evoke… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland